High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas

Katsuto Takenaka, Katsuji Shinagawa, Yoshinobu Maeda, Masanori Makita, Teruhiko Kozuka, Atsuko Ashiba, Kazuhiko Yamamoto, Nobuharu Fujii, Yuichiro Nawa, Yasushi Hiramatsu, Kazutaka Sunami, Fumihiko Ishimaru, Tadashi Yoshimo, Katsuyuki Kiura, Mine Harada

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

CD56+ natural killer (NK) cell lymphomas occur frequently in the nasal and nasopharyngeal regions and carry a poor prognosis. We have studied seven cases with NK-cell lymphomas. These lymphomas showed the following immunophenotype: CD56+, CD2+, sCD3- and Epstein-Barr virus-encoded small RNAs (EBERs)+. Six patients had localized (stage I or II) disease involving the nasopharyngeal region, while one had stage III disease. One patient with stage I disease achieved a complete remission (CR) after treatment with involved-field irradiation, but subsequently relapsed and died. The remaining six patients received combination chemotherapy as primary treatment: five patients with localized stage I or II disease and one patient with advanced stage III disease. Responses to initial chemotherapy were generally poor. These six patients received a variety of salvage chemotherapy regimens, but never achieved a CR. Subsequently, four of six patients showed a highly aggressive clinical course and died of disseminated disease within 1 year from the diagnosis. Three of six patients received high-dose chemotherapy supported by syngeneic, autologous or allogeneic peripheral blood stem cell transplantation. Two of the three transplant patients achieved a CR and are now surviving in continuous CR. Our clinical experience suggests that myeloablative high-dose chemotherapy and bone marrow rescue by hematopoietic stem cell transplantation may be an effective salvage treatment modality for refractory NK-cell lymphomas and could be considered as a part of the initial therapy for these patients.

Original languageEnglish
Pages (from-to)1297-1303
Number of pages7
JournalLeukemia and Lymphoma
Volume42
Issue number6
DOIs
Publication statusPublished - 2001

Fingerprint

Hematopoietic Stem Cell Transplantation
Nose
Natural Killer Cells
Lymphoma
Drug Therapy
Nasopharyngeal Diseases
Peripheral Blood Stem Cell Transplantation
Salvage Therapy
Combination Drug Therapy
Human Herpesvirus 4
Therapeutics
Bone Marrow
RNA
Transplants

Keywords

  • Hematopoietic stem cell transplantation
  • High-dose chemotherapy
  • Natural killer cell lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas. / Takenaka, Katsuto; Shinagawa, Katsuji; Maeda, Yoshinobu; Makita, Masanori; Kozuka, Teruhiko; Ashiba, Atsuko; Yamamoto, Kazuhiko; Fujii, Nobuharu; Nawa, Yuichiro; Hiramatsu, Yasushi; Sunami, Kazutaka; Ishimaru, Fumihiko; Yoshimo, Tadashi; Kiura, Katsuyuki; Harada, Mine.

In: Leukemia and Lymphoma, Vol. 42, No. 6, 2001, p. 1297-1303.

Research output: Contribution to journalArticle

Takenaka, K, Shinagawa, K, Maeda, Y, Makita, M, Kozuka, T, Ashiba, A, Yamamoto, K, Fujii, N, Nawa, Y, Hiramatsu, Y, Sunami, K, Ishimaru, F, Yoshimo, T, Kiura, K & Harada, M 2001, 'High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas', Leukemia and Lymphoma, vol. 42, no. 6, pp. 1297-1303. https://doi.org/10.1080/10428190127500
Takenaka, Katsuto ; Shinagawa, Katsuji ; Maeda, Yoshinobu ; Makita, Masanori ; Kozuka, Teruhiko ; Ashiba, Atsuko ; Yamamoto, Kazuhiko ; Fujii, Nobuharu ; Nawa, Yuichiro ; Hiramatsu, Yasushi ; Sunami, Kazutaka ; Ishimaru, Fumihiko ; Yoshimo, Tadashi ; Kiura, Katsuyuki ; Harada, Mine. / High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas. In: Leukemia and Lymphoma. 2001 ; Vol. 42, No. 6. pp. 1297-1303.
@article{9a2c924c15174d85ae26315068370118,
title = "High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas",
abstract = "CD56+ natural killer (NK) cell lymphomas occur frequently in the nasal and nasopharyngeal regions and carry a poor prognosis. We have studied seven cases with NK-cell lymphomas. These lymphomas showed the following immunophenotype: CD56+, CD2+, sCD3- and Epstein-Barr virus-encoded small RNAs (EBERs)+. Six patients had localized (stage I or II) disease involving the nasopharyngeal region, while one had stage III disease. One patient with stage I disease achieved a complete remission (CR) after treatment with involved-field irradiation, but subsequently relapsed and died. The remaining six patients received combination chemotherapy as primary treatment: five patients with localized stage I or II disease and one patient with advanced stage III disease. Responses to initial chemotherapy were generally poor. These six patients received a variety of salvage chemotherapy regimens, but never achieved a CR. Subsequently, four of six patients showed a highly aggressive clinical course and died of disseminated disease within 1 year from the diagnosis. Three of six patients received high-dose chemotherapy supported by syngeneic, autologous or allogeneic peripheral blood stem cell transplantation. Two of the three transplant patients achieved a CR and are now surviving in continuous CR. Our clinical experience suggests that myeloablative high-dose chemotherapy and bone marrow rescue by hematopoietic stem cell transplantation may be an effective salvage treatment modality for refractory NK-cell lymphomas and could be considered as a part of the initial therapy for these patients.",
keywords = "Hematopoietic stem cell transplantation, High-dose chemotherapy, Natural killer cell lymphoma",
author = "Katsuto Takenaka and Katsuji Shinagawa and Yoshinobu Maeda and Masanori Makita and Teruhiko Kozuka and Atsuko Ashiba and Kazuhiko Yamamoto and Nobuharu Fujii and Yuichiro Nawa and Yasushi Hiramatsu and Kazutaka Sunami and Fumihiko Ishimaru and Tadashi Yoshimo and Katsuyuki Kiura and Mine Harada",
year = "2001",
doi = "10.1080/10428190127500",
language = "English",
volume = "42",
pages = "1297--1303",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas

AU - Takenaka, Katsuto

AU - Shinagawa, Katsuji

AU - Maeda, Yoshinobu

AU - Makita, Masanori

AU - Kozuka, Teruhiko

AU - Ashiba, Atsuko

AU - Yamamoto, Kazuhiko

AU - Fujii, Nobuharu

AU - Nawa, Yuichiro

AU - Hiramatsu, Yasushi

AU - Sunami, Kazutaka

AU - Ishimaru, Fumihiko

AU - Yoshimo, Tadashi

AU - Kiura, Katsuyuki

AU - Harada, Mine

PY - 2001

Y1 - 2001

N2 - CD56+ natural killer (NK) cell lymphomas occur frequently in the nasal and nasopharyngeal regions and carry a poor prognosis. We have studied seven cases with NK-cell lymphomas. These lymphomas showed the following immunophenotype: CD56+, CD2+, sCD3- and Epstein-Barr virus-encoded small RNAs (EBERs)+. Six patients had localized (stage I or II) disease involving the nasopharyngeal region, while one had stage III disease. One patient with stage I disease achieved a complete remission (CR) after treatment with involved-field irradiation, but subsequently relapsed and died. The remaining six patients received combination chemotherapy as primary treatment: five patients with localized stage I or II disease and one patient with advanced stage III disease. Responses to initial chemotherapy were generally poor. These six patients received a variety of salvage chemotherapy regimens, but never achieved a CR. Subsequently, four of six patients showed a highly aggressive clinical course and died of disseminated disease within 1 year from the diagnosis. Three of six patients received high-dose chemotherapy supported by syngeneic, autologous or allogeneic peripheral blood stem cell transplantation. Two of the three transplant patients achieved a CR and are now surviving in continuous CR. Our clinical experience suggests that myeloablative high-dose chemotherapy and bone marrow rescue by hematopoietic stem cell transplantation may be an effective salvage treatment modality for refractory NK-cell lymphomas and could be considered as a part of the initial therapy for these patients.

AB - CD56+ natural killer (NK) cell lymphomas occur frequently in the nasal and nasopharyngeal regions and carry a poor prognosis. We have studied seven cases with NK-cell lymphomas. These lymphomas showed the following immunophenotype: CD56+, CD2+, sCD3- and Epstein-Barr virus-encoded small RNAs (EBERs)+. Six patients had localized (stage I or II) disease involving the nasopharyngeal region, while one had stage III disease. One patient with stage I disease achieved a complete remission (CR) after treatment with involved-field irradiation, but subsequently relapsed and died. The remaining six patients received combination chemotherapy as primary treatment: five patients with localized stage I or II disease and one patient with advanced stage III disease. Responses to initial chemotherapy were generally poor. These six patients received a variety of salvage chemotherapy regimens, but never achieved a CR. Subsequently, four of six patients showed a highly aggressive clinical course and died of disseminated disease within 1 year from the diagnosis. Three of six patients received high-dose chemotherapy supported by syngeneic, autologous or allogeneic peripheral blood stem cell transplantation. Two of the three transplant patients achieved a CR and are now surviving in continuous CR. Our clinical experience suggests that myeloablative high-dose chemotherapy and bone marrow rescue by hematopoietic stem cell transplantation may be an effective salvage treatment modality for refractory NK-cell lymphomas and could be considered as a part of the initial therapy for these patients.

KW - Hematopoietic stem cell transplantation

KW - High-dose chemotherapy

KW - Natural killer cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=18244385267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244385267&partnerID=8YFLogxK

U2 - 10.1080/10428190127500

DO - 10.1080/10428190127500

M3 - Article

C2 - 11911411

AN - SCOPUS:18244385267

VL - 42

SP - 1297

EP - 1303

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -